ImmunityBio, Inc. has grown revenue 554% a year over three years and 203% a year over five. Revenue growth, 3-year annual rate: +554% (Biotechnology median +17%). Revenue growth, 5-year rate: +203%, growth has picked up over the last three years. Years of annual history on file: 13, FY2013 to FY2025, as filed.

IBRXImmunityBio, Inc.

Healthcare

$10.51+285% 1Y

$10.51

$1.9852 weeks$11.55

Is it growing?

Good

Growing: revenue growing +193% year on year and operating margin widening (+568.1 points).

2 good, 1 without data

Revenue trend+193% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +203% a year.

Margin direction+568.1 points operating

Trailing-twelve-month operating margin, -155.2% now against -723.3% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is IBRX growing?

ImmunityBio, Inc. has grown revenue 554% a year over three years and 203% a year over five.

+554%

Revenue growth, 3-year annual rate · Biotechnology median +17% · compounding fast · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +203%
Revenue growth, 5-year rate · +554% over three · growth has picked up over the last three years
Years of annual history on file: 13
Years of annual history on file · FY2013 to FY2025, as filed

Details›